<DOC>
	<DOCNO>NCT00270283</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety epoetin alfa AIDS patient treatment anemia result disease zidovudine ( AZT ) treatment . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Epoetin Alfa Versus Placebo Treatment Anemia Patients With Acquired Immunodeficiency Syndrome ( AIDS ) Who Are Receiving Zidovudine ( AZT ) Therapy</brief_title>
	<detailed_description>It estimate approximately 75 % 80 % patient AIDS experience anemia , cause AIDS therapy patient receive AIDS treatment ( example , zidovudine [ AZT ] ) . Anemia condition patient normal level hemoglobin , substance red blood cell carry oxygen part body . People severe anemia may experience fatigue shortness breath activity . Therefore , condition negative influence person 's quality life . Epoetin alfa , use treat anemia , genetically engineer form natural hormone , erythropoietin , stimulates red blood cell production . This randomized , double-blind , placebo-controlled , parallel group study open-label follow-up period design evaluate safety effectiveness epoetin alfa treatment patient AIDS treat AZT . The study consist 3 period : screening period determine patient eligible study , double-blind treatment period , open-label treatment period . Eligible patient randomly assign one two group : epoetin alfa 150 unit per kilogram matching placebo . Patients treat study medication ( injected skin ) 3 time week 12 week , hematocrit reach 38 % 40 % . In open-label period , patient receive epoetin alfa inject skin 6 month . Effectiveness determine change hemoglobin hematocrit ( laboratory test use evaluate severity anemia ) , transfusion requirement , patient 's quality life assessment , physician 's global evaluation drug effect . Safety assessment include incidence severity adverse event study , change clinical laboratory test ( hematology , biochemistry , urinalysis ) , vital sign , electrocardiogram ( ECGs ) , physical examination finding . The study hypothesis AIDS patient receive AZT treat epoetin alfa lower incident anemia compare patient receive placebo . Double-blind : epoetin alfa , 150 unit per kilogram [ U/kg ] body weight , placebo , inject patient 's skin 3 time week 12 week hematocrit level reach 38 % 40 % . Open-label : epoetin alfa , 200 U/kg , 3 time week 6 month ( weekly hematocrit reach 38 % 40 % ) . Dose may adjust 1500 U/kg per week , need .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Patients confirm diagnosis AIDS Performance score 0 , 1 , 2 ( patient ' ability perform daily activity , score range 0 [ fully active , disease restriction ] 3 [ capable limited selfcare , confine bed chair 50 % waking hour ] ) take maintenance dose AZT least 400 mg/day hematocrit least 30 % history &gt; =15 % decrease hematocrit since start AZT therapy , become dependent transfusion clinically stable least 1 month study entry . Patients history important blood disease clinically significant disease malfunction lung , heart , hormone , neurological , gastrointestinal , reproductive urinary system , cause AIDS infection dementia due AIDS , history seizure , uncontrolled high blood pressure , iron deficiency androgen therapy within 2 month study entry anemia cause condition AIDS AZT therapy ( example , certain vitamin deficiency bleed gastrointestinal tract ) sudden onset infection , history cell damage due chemotherapy within 1 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Anemia</keyword>
	<keyword>AIDS</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV</keyword>
</DOC>